@article {1614,
	title = {A trial of integrated buprenorphine/naloxone and HIV clinical care.},
	journal = {Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
	volume = {43 Suppl 4},
	year = {2006},
	month = {2006 Dec 15},
	pages = {S184-90},
	abstract = {Untreated opioid dependence adversely affects the care of human immunodeficiency virus (HIV)-positive patients. Buprenorphine, a partial opioid agonist, is available for maintenance treatment of opioid dependence in HIV specialty settings. We investigated the feasibility and efficacy of integrating buprenorphine, along with 2 levels of counseling, into HIV clinical care.},
	keywords = {Administration, Sublingual, Adult, Antiretroviral Therapy, Highly Active, Buprenorphine, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, HIV Infections, Humans, Male, Middle Aged, Naloxone, Narcotic Antagonists, Opioid-Related Disorders, Pilot Projects, Probability, Reference Values, Risk Factors, Treatment Outcome},
	issn = {1537-6591},
	doi = {10.1111/j.1475-6773.2011.01335.x},
	author = {Sullivan, Lynn E and Barry, Declan and Moore, Brent A and Chawarski, Marek C and Tetrault, Jeanette M and Pantalon, Michael V and O{\textquoteright}Connor, Patrick G and Schottenfeld, Richard S and Fiellin, David A}
}
